Results 181 to 190 of about 981,832 (295)
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy +10 more
wiley +1 more source
Educational needs in neuro-oncology: Insights from the European Society for Medical Oncology Central Nervous System Faculty Survey. [PDF]
Mirallas O +13 more
europepmc +1 more source
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel +12 more
wiley +1 more source
Supplementum 283: Abstracts of the Swiss Oncology & Hematology Congress (SOHC)
Swiss Society of Medical Oncology +2 more
doaj +1 more source
Impact of Clinical Pharmacists' Interventions on Medication Use and Direct Cost Savings in an Inpatient Medical Oncology Setting. [PDF]
Faqeer N +4 more
europepmc +1 more source
Eighteen Years of Medical Oncology in Morocco: A Bibliometric Evaluation. [PDF]
Kaakoua M +4 more
europepmc +1 more source
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
European Society for Medical Oncology (ESMO) Gastrointestinal Cancers congress 2025. [PDF]
Nedic I.
europepmc +1 more source
Medical Oncology Group of Australia Annual Scientific Meeting, August 2-4, 2023. [PDF]
Caga-Meller J.
europepmc +1 more source
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source

